Activated protein C resistance in patients with central retinal vein occlusion

J Larsson, A Sellman, B Bauer

Abstract
Aim/background—A new defect in the anticoagulant system has recently been discovered—activated protein C resistance. The frequency of this disorder has been shown to be increased in young patients (<50 years of age) with central retinal vein occlusion. This study was carried out to determine if there was any overrepresentation of activated protein C resistance in patients >50 years of age with central retinal vein occlusion.

Methods—Blood samples were obtained from 83 patients >50 years of age and with a history of central retinal vein occlusion. The blood samples were analysed for activated protein C resistance with standard clinical laboratory methods.

Results—In this material 11% of the patients were resistant to activated protein C. The normal incidence of activated protein C resistance in the same geographical area is 10–11%.

Conclusion—Activated protein C resistance does not seem to be a cause of central retinal vein occlusion in people older than 50 years.

Central retinal vein occlusion (CRVO) is a disease that is fairly common in elderly people. Glaucoma, hypertension, atherosclerosis, and diabetes are factors that are well known to be associated with the disease.1 Hereditary deficiencies in the coagulation system have never been proved to be an important factor in the aetiology of CRVO. In patients with a diagnosis of thrombophilia, hereditary deficiencies in the coagulation system have been found only in 4–6%.2 3

In 1992 Dahlbäck et al discovered that some young patients with thrombosis had a resistance to activated protein C.4 5 Although activated protein C (APC) was added to the patients’ plasma it did not result in the normal inhibition of the coagulation. Later they were able to show that this was due to a selective defect in the anticoagulant function of factor Va. The defect is a point mutation that has been localised to the locus for the factor V gene on chromosome 1-IV 506,6 8 and it is dominantly inherited.9

The prevalence of this mutation varies between 2% and 15% depending on the geographical area.7 10–12 It is absent in African, Japanese, and Chinese people11 14 and has one of its peak figures in southern Sweden where it reaches 10–15% in the population.13 The risk of thrombosis is increased five to tenfold in heterozygotes and 50–100-fold in homozygotes.15–18 Several patients with a history of thrombosis, mainly in the leg, have been examined with regard to APC resistance and the prevalence has been found to vary between 21% to 52%, with the higher values if there is a history of thrombophilia in the family.7 19 20

We have recently shown that activated protein C resistance was increased fourfold in a group of young patients with CRVO, aged less than 50.21 We wanted to find out whether patients above that age also had an overrepresentation of APC resistance and the IV 506 mutation.

Patients and methods

PATIENTS

The population sample was recruited from the patient records of the eye clinics of the Lund University Hospital and the Helsingborg Medical Center Hospital in Helsingborg, Sweden. Of the 108 patients found, blood samples were obtainable from 83. They comprised 45 (54%) males and 38 (46%) females. The average age was 70 years (range 50–92 years).

The control patients collected by Holm et al15 from the University Hospital in Malmö were used since they belong to the same geographical area. All the patients were from the same geographical area, which could be defined as a circle with a diameter no more than 80 km. This is important since we know that the frequency of APC resistance varies with even fairly small geographical distances.

METHODS

The analysis of resistance to APC was carried out at the Department of Clinical Chemistry, Malmö, Sweden. The method is the same as that described by Dahlbäck et al.22 Seventy five of the patients were also tested with the modified APC resistance test in which the plasma samples were diluted 1/5 in factor V deficient
Activated protein C resistance in patients with central retinal vein occlusion

Williamson

This study of 83 patients shows that APC resistance when their plasma samples had an APC ratio less than 2.4 in the standard test and 1.9 in the modified test. All patients that showed APC resistance in the test were screened for the fV506 mutation. The patients who had borderline APC ratios—that is, <2.2 in the modified test, were also screened for the fV506 mutation.

Results

Nine (11%) patients were APC resistant and they did all have the fV506 mutation. Of these nine, eight were heterozygotes and one was homozygous for the mutation. The average APC ratio in the modified test for these patients was 1.5 (range 1.1–1.6). The average APC ratio in the modified test in the remaining patients was 2.3 (range 2.5–2.2).

Four patients had an APC ratio of 2.1 in the modified test and were thus screened for the fV506 mutation, but none of them had the mutation.

Discussion

This study of 83 patients shows that APC resistance is not more common in patients younger than 50 years and with a diagnosis of CRVO, whereas they examined those with BRVO and CRVO.

Since the most important risk factors for central retinal vein occlusion—glaucoma, hypertension, and atherosclerosis—are factors that are much more common in the elderly, it is probable that these factors have such an impact on the aetiology to CRVO that APC resistance is of less importance. On the other hand, in younger people glaucoma, hypertension, and atherosclerosis are much less common, and a deficiency in the coagulation system is more likely to be the triggering factor for thrombosis.

In conclusion, we have shown that activated protein C resistance does not seem to be an important factor in the aetiology of CRVO in patients older than 50 years.
6 Dahlbäck B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994;24:139–51.


